Kircik Leon H
Indiana University School of Medicine, Indianapolis, Indiana; Mount Sinai Medical Center, New York, New York; DermResearch, PLLC, Louisville, Kentucky.
J Clin Aesthet Dermatol. 2011 May;4(5):27-31.
Initiation of effective topical therapy as early as possible within the disease course is associated with improved patient experiences and better therapeutic outcomes in most dermatological diseases. Additionally, patient adherence is associated with better outcomes and lower long-term treatment costs, while poor adherence is directly linked to poor treatment results and patient dissatisfaction. Local cutaneous irritation associated with topical drug formulations has been an historical challenge to therapy initiation and adherence. Retinoids and benzoyl peroxide-essential elements of topical acne treatment-are two of the drugs most commonly associated with application-site adverse events. Novel approaches to product formulation incorporating microsphere technology may improve treatment tolerability, encourage adherence, and contribute to better long-term therapeutic outcomes. Microsphere technology eliminates the rapid delivery of high concentrations of active drug to the application site and instead facilitates controlled release of potentially irritating drugs. It is associated with improved treatment outcomes and minimal irritation. Microsphere formulations of topical tretinoin and benzoyl peroxide currently on the market have demonstrated good efficacy and tolerability and are expected to encourage adherence and long-term therapeutic benefit.
在大多数皮肤病病程中尽早开始有效的局部治疗与改善患者体验及更好的治疗效果相关。此外，患者的依从性与更好的治疗效果及更低的长期治疗成本相关，而依从性差则直接与治疗效果不佳和患者不满相关。与局部用药制剂相关的局部皮肤刺激一直是治疗开始和依从性方面的一个历史性挑战。维甲酸和过氧化苯甲酰——局部治疗痤疮的基本要素——是两种最常与用药部位不良事件相关的药物。采用微球技术的新型产品配方方法可能会提高治疗耐受性，促进依从性，并有助于实现更好的长期治疗效果。微球技术消除了高浓度活性药物向用药部位的快速释放，而是促进了潜在刺激性药物的控释。它与改善治疗效果和最小化刺激相关。目前市场上的局部维甲酸和过氧化苯甲酰微球制剂已显示出良好的疗效和耐受性，有望促进依从性和长期治疗益处。
